GERN insider transaction filings
GERON CORP — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-01. Screen GERN transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 1 Form 4 filing. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 1.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Spiegel Robert J. — Director | 1 | — | — | 1 |
Recent Form 4 filings — GERON CORP
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-01 | 4 | Spiegel Robert J. — Director | Grant/award (A): 6,103 @ $1.28 | EDGAR |
| 2026-05-26 | 4 | McDonald John F — Director | Grant/award (A): 220,000 (derivative) @ $0 | EDGAR |
| 2026-05-26 | 4 | O'Farrell Elizabeth G. — Director | Grant/award (A): 220,000 (derivative) @ $0 | EDGAR |
| 2026-05-26 | 4 | Bir Dawn Carter — Director | Grant/award (A): 220,000 (derivative) @ $0 | EDGAR |
| 2026-05-26 | 4 | Molineaux Susan — Director | Grant/award (A): 220,000 (derivative) @ $0 | EDGAR |
| 2026-05-26 | 4 | Spiegel Robert J. — Director | Grant/award (A): 220,000 (derivative) @ $0 | EDGAR |
| 2026-04-14 | 4 | Williams Timothy — EVP and Chief Legal Officer | Grant/award (A): 2,500,000 (derivative) @ $0 | EDGAR |
| 2026-04-01 | 4 | Spiegel Robert J. — Director | Grant/award (A): 5,243 @ $1.49 | EDGAR |
| 2026-03-26 | 4 | Chinoporos Constantine — Director | Grant/award (A): 270,000 (derivative) @ $0 | EDGAR |
| 2026-03-26 | 4 | Andrews Patricia S — Director | Grant/award (A): 270,000 (derivative) @ $0 | EDGAR |
| 2026-02-19 | 4 | Eid Joseph — EVP, R&D; Chief Medical Office | Grant/award (A): 2,220,000 (derivative) @ $0 | EDGAR |
| 2026-02-19 | 4 | ROBERTSON MICHELLE — EVP, CHIEF FINANCIAL OFFICER | Option exercise (M): 27,500 @ $0 · Sale (S): 9,855 @ $1.94 · Grant/award (A): 1,660,000 (derivative) @ $0 · Option exercise (M): 27,500 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Spiegel Robert J. — Director | Grant/award (A): 5,918 @ $1.32 | EDGAR |
| 2025-10-20 | 4 | ElNawawi Ahmed — EVP, Chief Commercial Officer | Grant/award (A): 3,000,000 (derivative) @ $0 | EDGAR |
| 2025-10-01 | 4 | Spiegel Robert J. — Director | Grant/award (A): 5,702 @ $1.37 | EDGAR |
| 2025-08-08 | 4 | Semerjian Harout — President and CEO, Director | Grant/award (A): 7,000,000 (derivative) @ $0 · Grant/award (A): 4,000,000 (derivative) @ $0 | EDGAR |
| 2025-07-01 | 4 | Spiegel Robert J. — Director | Grant/award (A): 5,540 @ $1.41 | EDGAR |
| 2025-05-22 | 4 | McDonald John F — Director | Grant/award (A): 180,000 (derivative) @ $0 | EDGAR |
| 2025-05-22 | 4 | O'Farrell Elizabeth G. — Director | Grant/award (A): 180,000 (derivative) @ $0 | EDGAR |
| 2025-05-22 | 4 | Bir Dawn Carter — Interim President and CEO, Director | Grant/award (A): 180,000 (derivative) @ $0 | EDGAR |
| 2025-05-22 | 4 | Molineaux Susan — Director | Grant/award (A): 180,000 (derivative) @ $0 | EDGAR |
| 2025-05-22 | 4 | Aggarwal Gaurav — Director | Grant/award (A): 180,000 (derivative) @ $0 | EDGAR |
| 2025-05-22 | 4 | Spiegel Robert J. — Director | Grant/award (A): 180,000 (derivative) @ $0 | EDGAR |
| 2025-05-22 | 4 | LAWLIS V BRYAN — Director | Grant/award (A): 180,000 (derivative) @ $0 | EDGAR |
| 2025-05-13 | 4 | LAWLIS V BRYAN — Director | Purchase (P): 13,300 @ $1.18 | EDGAR |
| 2025-04-02 | 4 | Spiegel Robert J. — Director | Grant/award (A): 4,913 @ $1.59 | EDGAR |
| 2025-04-02 | 4/A | Spiegel Robert J. — Director | Grant/award (A): 2,206 @ $3.54 | EDGAR |
| 2025-04-02 | 4/A | Spiegel Robert J. — Director | Grant/award (A): 1,767 @ $4.54 | EDGAR |
| 2025-04-02 | 4/A | Spiegel Robert J. — Director | Grant/award (A): 2,462 @ $3.30 · Grant/award (A): 1,916 @ $4.24 | EDGAR |
| 2025-03-03 | 4 | Ziegler James — EVP, Chief Commercial Officer | Purchase (P): 100,000 @ $1.60 | EDGAR |
| 2025-03-03 | 4 | Samuels Scott Alan — EVP, Chief Legal Officer | Purchase (P): 15,000 @ $1.61 | EDGAR |
| 2025-03-03 | 4 | SCARLETT JOHN A — Chairman, President and CEO, Director | Purchase (P): 12,500 @ $1.76 | EDGAR |
| 2025-02-20 | 4 | Ziegler James — EVP, Chief Commercial Officer | Grant/award (A): 529,000 (derivative) @ $0 · Grant/award (A): 89,000 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | Samuels Scott Alan — EVP, Chief Legal Officer | Grant/award (A): 621,000 (derivative) @ $0 · Grant/award (A): 104,000 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | ROBERTSON MICHELLE — EVP, Chief Financial Officer | Grant/award (A): 656,000 (derivative) @ $0 · Grant/award (A): 110,000 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | SCARLETT JOHN A — Chairman, President and CEO, Director | Grant/award (A): 2,457,000 (derivative) @ $0 · Grant/award (A): 410,000 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | GRETHLEIN ANDREW J — EVP, Chief Operating Officer | Grant/award (A): 839,000 (derivative) @ $0 · Grant/award (A): 140,000 (derivative) @ $0 | EDGAR |
| 2025-01-02 | 4 | Spiegel Robert J. — Director | Grant/award (A): 2,206 @ $0 | EDGAR |
| 2024-11-12 | 4 | Eid Joseph — EVP, Research and Development | Grant/award (A): 2,500,000 (derivative) @ $0 | EDGAR |
| 2024-10-01 | 4 | Spiegel Robert J. — Director | Grant/award (A): 1,767 @ $0 | EDGAR |
| 2024-09-09 | 4 | Ziegler James — EVP, Chief Commercial Officer | Grant/award (A): 1,600,000 (derivative) @ $0 | EDGAR |
| 2024-07-10 | 4 | GRETHLEIN ANDREW J — EVP, Chief Operating Officer | Option exercise (M): 674,348 @ $1.72 · Sale (S): 674,348 @ $4.56 · Option exercise (M): 221,544 (derivative) @ $0 · Option exercise (M): 452,804 (derivative) @ $0 | EDGAR |
| 2024-06-28 | 4 | Spiegel Robert J. — Director | Grant/award (A): 2,462 @ $0 · Grant/award (A): 1,916 @ $0 | EDGAR |
| 2024-06-12 | 4 | Feller Faye — EVP, Chief Medical Officer | Option exercise (M): 112,500 @ $1.06 · Option exercise (M): 20,000 @ $1.06 · Option exercise (M): 155,400 @ $1.29 · Sale (S): 287,900 @ $4.63 · Option exercise (M): 112,500 (derivative) @ $0 · Option exercise (M): 20,000 (derivative) @ $0 · +1 more | EDGAR |
| 2024-06-12 | 4 | Kapur Anil — EVP, Corp Strategy & CCO | Option exercise (M): 421,875 @ $1.06 · Sale (S): 421,875 @ $4.64 · Option exercise (M): 421,875 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Feller Faye — EVP, Chief Medical Officer | Grant/award (A): 50,000 (derivative) @ $0 · Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | ROBERTSON MICHELLE — EVP, Chief Financial Officer | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Kapur Anil — EVP, Corp Strategy & CCO | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | SCARLETT JOHN A — Chairman, President and CEO, Director | Grant/award (A): 1,000,000 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | GRETHLEIN ANDREW J — EVP, Chief Operating Officer | Grant/award (A): 452,804 (derivative) @ $0 | EDGAR |
Recent 8-K events — GERON CORP
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-27 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-26 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-02-25 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-06 | 8-K | 1.01 — Entry into a Material Definitive Agreement | EDGAR |
| 2025-12-16 | 8-K | ? | EDGAR |
| 2025-11-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-14 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=GERN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →